Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shinjuku-ku
Clinical trial register · Japan

Clinical Trials in Shinjuku-ku, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca14 Novartis Pharmaceuticals14 Eli Lilly and Company13 AbbVie7 Pfizer6
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Shinjuku-ku

107 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Kurume-shi, Sapporo, Kumamoto, Kyoto, Matsumoto-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku
2027-11-23
Not yet open
Eli Lilly and Company
Phase 3
2,115
Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe
2026-12
Not yet open
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-10-15
Not yet open
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
NCT07872449Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease
DrugRisankizumab
Yuki Horio
Phase 4
25
Nishinomiya, Shinjuku-Ku, Yokohama
2026-10-01
Recruiting
Amgen
Phase 3
3,200
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2026-07-23
Recruiting
Takeda
Phase 2
9
Nagoya, Maebashi, Tsu, Suita, Bunkyo-ku, Shinjuku-ku, Sumida-ku, Chūō
2026-07-14
Recruiting
AstraZeneca
Phase 3
2,000
Chūōku, Hachioji-shi, Ichikawa-shi, Kishiwada-shi, Meguro-ku, Mito, Sapporo, Shinjuku-ku
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Amagasaki-shi, Chūōku, Kasugai-shi, Koga-shi, Maebashi, Minatoku, Naka, Shinjuku-ku
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Fukuoka, Kyoto, Nishinomiya-shi, Okayama, Sapporo, Shibuya-ku, Shinjuku-ku, Suita-shi
2026-06-26
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
DrugTAK-360
Takeda
Phase 2/3
500
Kumamoto, Shinjuku-ku
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
Bunkyō City, Kurume-shi, Sapporo, Shinjuku-ku, Suita
2026-06-11
Recruiting
Pfizer
Phase 3
954
Suita, Chuo-ku, Shinjuku-ku
2026-06-10
Recruiting
Takeda
Phase 2
92
Fukuoka, Kumamoto, Isahaya-shi, Yodogawa-ku, Osaka-shi, Shinjuku-ku
2026-06-04
Recruiting
AbbVie
Phase 1
30
Nagoya, Bunkyo-ku, Shinjuku-ku
2026-05-28
Recruiting
Hoffmann-La Roche
Phase 3
138
Kashihara-shi, Shinjuku-Ku
2026-05-15
Recruiting
Novartis Pharmaceuticals
Phase 2
323
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2026-05-07
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Fujiidera, Isehara, Kobe, Kumamoto, Sapporo, Shinjuku-Ku
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Chūōku, Isehara, Kobe, Sapporo, Shinjuku-Ku
2026-04-29
Recruiting
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku, Kumamoto, Tokyo
2026-04-22
Recruiting
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
Pfizer
Phase 1/2
132
Shinjuku-ku, Fukuoka, Yamagata
2026-03-11
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Nagoya, Urayasu, Shinjuku Ku, Kofu, Niigata
2026-03-09
Recruiting
AusperBio Therapeutics Inc.
Phase 2
84
Musashino, Shinjuku-Ku
2026-03-06
Recruiting
AstraZeneca
Phase 3
508
Bunkyō City, Kashiwa, Kyoto, Nagoya, Shibuya-ku, Shinjuku-ku
2026-02-23
Recruiting
Pfizer
Phase 1/2
224
Yokohama, Suita, Shinjuku-ku, Fukuoka, Yamagata
2026-02-10
Recruiting
Eli Lilly and Company
Phase 1
68
Shinjuku-ku
2026-02-04
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Hiroshima, Asahikawa, Bunkyo-ku, Fuchu-shi, Setagaya-ku, Shinjuku-ku
2025-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Matsudo, Takamatsu, Miyhazaki, Suita, Shinjuku Ku, Kyoto
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Chūōku, Hamadayama, Suginami-ku, Izumisano, Kobe, Kofu, Kumamoto, Shinjuku-ku, Takarazuka
2025-12-01
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
2025-11-24
Active, closed
AstraZeneca
Phase 3
212
Kawasaki-shi, Kodaira-shi, Minatoku, Ōta-ku, Shinjuku-ku, Yokohama, Yufu-shi
2025-08-07
Recruiting
AstraZeneca
Phase 2
278
Bunkyō City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 2
97
Ōbu, Fujioka, Itabashi Ku, Kodaira, Shinjuku Ku
2025-08-07
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Recruiting
Tokyo Women's Medical University
Not applicable
5
Shinjuku-Ku
2025-07-03
Active, closed
Eli Lilly and Company
Phase 3
600
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-19
Active, closed
Eli Lilly and Company
Phase 3
800
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Active, closed
Eli Lilly and Company
Phase 3
1,400
Chitose, Chūōku, Mihama-ku,Chiba City, Shinjuku-ku, Suita-shi, Takamatsu, Tokyo, Tsuchiura
2025-05-15
Recruiting
Takeda
Phase 2
88
Kohoku-ku, Yokohama-Shi, Kumamoto, Isahaya-shi, Urasoe-Shi, Shinjuku-ku, Sumida-Ku, Fukuoka, Yodogawa-ku, Osaka-shi
2025-05-06
Recruiting
Keio University
Phase 4
100
Shinjuku-ku
2025-04-10
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Suita, Chuo Ku, Chuo-ku, Shinjuku Ku
2025-03-26
Active, closed
Novartis Pharmaceuticals
Phase 2
126
Chiba, Sapporo, Kobe, Sendai, Suita, Bunkyo Ku, Shinjuku-ku, Fukuoka
2025-03-13
Active, closed
Amgen
Phase 3
3,853
Yokohama, Chiyoda-ku, Chuo-ku, Hachioji-shi, Minato-ku, Shinjuku-ku, Suginami-ku
2025-03-12
Recruiting
AbbVie
Phase 3
420
Kobe, Kochi, Osaka, Shibuya-ku, Shinjuku-ku, Tendo-shi, Kai, Kagoshima
2025-02-13
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Sapporo, Nishinomiya, Hanamaki, Sendai, Suita, Higashi-Matsuyama, Koshigaya, Shinjuku Ku
2025-02-07
Recruiting
Enliven Therapeutics
Phase 1
21
Akita, Sapporo, Suita-shi, Shinjuku-ku
2025-01-23
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Sapporo, Yokohama, Sendai, Suita, Izumo, Bunkyo-ku, Shinjuku-ku, Fukuoka
2024-12-17
By invitation
CoreTissue BioEngineering Inc.
Not applicable
64
Hirosaki, Hiroshima, Sapporo, Kobe, Bunkyo-ku, Shinjuku-ku
2024-11-25
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nagoya, Toyoake, Yokohama, Iruma-gun, Bunkyo-ku, Shinjuku Ku, Toyama, Hiroshima
2024-10-09
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Bunkyō City, Fukuoka, Mitaka, Nagoya, Okayama, Shinjuku-Ku, Suita
2024-09-03
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Chofu-shi, Chūōku, Hirakata-shi, Kobe, Musashimurayama, Narashino-shi, Shinjuku Ku, Shinjuku-ku
2024-07-22
Recruiting
CSL Behring
Phase 2/3
3,110
Ichinomiya-shi, Urayasu-shi, Kitakyushu-shi, Maebashi, Sapporo, Kusatsu-shi, Shinjuku-Ku, Hashima-gun
2024-04-27
Recruiting
AstraZeneca
Phase 3
100
Bunkyō City, Chiba, Fuchu-shi, Kawasaki-shi, Kobe, Nagasaki, Obu-shi, Shinjuku-ku
2024-03-14
Active, closed
Astellas Gene Therapies
Not applicable
119
Kodaira-Shi, Shinjuku-Ku
2024-02-01
Active, closed
Incyte Corporation
Phase 3
617
Ginowan-shi, Itabashi-ku, Kurume-shi, Kyoto, Niigata, Sapporo, Sendai, Shinjuku-ku
2024-01-30
Active, closed
Pfizer
Phase 3
394
Nagoya, Sendai, Sakai, Bunkyo-ku, Shinjuku-ku, Kofu
2024-01-19
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Bunkyō City, Kumamoto, Kurume-shi, Kyoto, Matsumoto-shi, Sapporo, Shinjuku-ku, Suita-shi
2024-01-11
Active, closed
AbbVie
Phase 3
614
Nagoya, Sakai-shi, Suita-shi, Bunkyo-ku, Shinjuku-ku, Yamagata, Kofu
2023-12-19
Recruiting
AbbVie
Phase 3
1,500
Kurume-shi, Sagamihara-shi, Niigata, Osaka, Hamamatsu, Mitaka-shi, Shinjuku-ku, Ube-shi
2023-10-11
Active, closed
AstraZeneca
Phase 1/2
166
Fukuoka, Shinjuku-ku, Suita-shi
2023-09-29
Recruiting
GramEye
Observational
15,000
Shinjuku-Ku
2023-09-25
Recruiting
MiMedx Group, Inc.
Not applicable
75
Kobe, Iruma-gun, Bunkyō-Ku, Mitaka-shi, Shinjuku-Ku
2023-08-04
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
16
Chikushino-shi, Sendai, Nishihara, Suita, Bunkyo-ku, Minato-ku, Shinjuku-ku, Asahikawa
2023-08-01
By invitation
AbbVie
Phase 3
650
Kobe, Nishinomiya-shi, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-06-05
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
Toyonaka-shi, Kodaira, Shinjuku-ku
2023-05-31
Recruiting
Pfizer
Phase 3
318
Kitakyushu-shi, Kawasaki, Sendai, Okayama, Ōtsu, Bunkyo-ku, Shinjuku-ku, Ube
2023-05-20
Recruiting
AbbVie
Phase 3
450
Kobe, Nishinomiya, Kochi, Sendai, Osaka, Shinjuku-ku, Kyoto
2023-05-01
Active, closed
Merck Sharp & Dohme LLC
Phase 3
641
Nagoya, Bunkyo, Shinjuku-ku, Shinjyuku-ku, Osaka
2023-03-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Nagoya, Shinjuku-ku, Shinjyuku-ku, Osaka
2023-03-08
Recruiting
Eli Lilly and Company
Phase 3
595
Hamamatsu, Kurume, Mitaka, Miyagi-gun, Niigata, Osaka, Shinjuku-ku, Ube
2023-02-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
553
Nagoya, Shinjuku-ku, Shinjyuku-ku
2023-02-20
Active, closed
TRISCEND JAPAN Study
NCT05760989Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Not applicable
45
Kitakyushu-shi, Isehara-shi, Sendai, Osaka, Suita, Suita-shi, Shinjuku-Ku
2023-02-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Nagoya, Asahikawa, Chuo Ku, Hamamatsu, Shinjuku-Ku, Osaka
2023-01-05
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Narita, Matsuyama, Gifu, Kobe, Isehara, Suita, Itabashi-ku, Shinjuku Ku
2022-12-30
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Kurume, Shinjuku Ku
2022-12-19
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugsErythromycin·Rina-S·Itraconazole·Bevacizumab
Genmab
Phase 1/2
952
Fukushima, Ōta, Sapporo, Akashi, Hidaka, Nagaizumi-chō, Koto, Shinjuku-ku
2022-12-07
Active, closed
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
NCT05814159Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
DrugAnakinra
Swedish Orphan Biovitrum
Phase 3
15
Fukushima, Kobe, Yokohama, Matsumoto, Bunkyō-Ku, Shinjuku-Ku, Gifu
2022-08-24
Recruiting
Janssen Research & Development, LLC
Phase 2/3
12
Azumino-shi, Chiba, Miyazaki, Nishinomiya-Shi, Saitama Shi, Shinjuku-ku
2022-07-20
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Shinjuku-ku, Fukuoka, Itabashi-ku, Kumamoto, Mitaka, Miyazaki, Sendai, Tsu
2022-06-30
Active, closed
Hoffmann-La Roche
Phase 2/3
97
Hyōgo, Kagoshima, Shinjuku-ku
2022-06-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
120
Ōbu, Kurume-shi, Komatsu, Yokohama, Takatsuki, Bunkyo-Ku, Setagaya-ku, Shinjuku-ku
2022-05-30
Active, closed
National Center for Global Health and Medicine, Japan
Phase 4
567
Shinjuku-Ku
2022-05-26
Active, closed
UCB Biopharma SRL
Phase 3
113
Chiba, Isehara, Kitakyushu-shi, Kodaira, Koriyama-shi, Sendai, Shinjuku-ku, Suita-shi
2022-02-02
Recruiting
Novartis Pharmaceuticals
Phase 1/2
34
Yokohama, Shinjuku-ku, Osaka
2021-12-27
Active, closed
AstraZeneca
Phase 3
145
Minatoku, Nagoya, Shinjuku-ku
2021-11-19
Active, closed
AstraZeneca
Phase 3
927
Chūōku, Hidaka-shi, Hiroshima, Kawasaki-shi, Kōtoku, Nagoya, Ota-shi, Shinjuku-ku
2021-10-25
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Kurume, Suita, Chuo Ku, Minato-Ku, Shinjuku-Ku, Matsuyama, Nagoya, Niigata
2021-10-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
2,000
Nagoya, Shinjuku-ku, Shinjyuku-ku, Osaka, Tokyo
2021-09-15
Active, closed
Eli Lilly and Company
Phase 3
2,996
Bunkyō City, Chūōku, Hachiōji, Osaka, Ōbu, Shinjuku, Shinjuku-ku, Suita-shi
2021-08-27
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
32
Kashiwa-shi, Yokohama, Hamamatsu, Bunkyō-Ku, Koto-ku, Mitaka-shi, Shinjuku-Ku, Chūōku
2021-07-30
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Nagoya, Isehara, Suwa, Suita, Shinjuku Ku, Fukushima, Ishikawa, Kyoto
2021-07-27
Active, closed
AbbVie
Phase 3
132
Nagoya, Tsu, Hirakata-shi, Shinjuku-ku
2021-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
342
Nishinomiya, Kawasaki, Sagamihara, Suita, Hidaka, Shinjuku-ku, Chiba, Fukuoka
2021-06-18
Recruiting
Bristol-Myers Squibb
Phase 3
153
Nagoya, Fukuoka, Jonan-Ku, Isehara, Tsu, Itabashi-ku, Shinjuku-ku, Osaka
2021-03-23
Active, closed
Bioverativ, a Sanofi company
Phase 3
261
Nagoya, Kitakyushu-shi, Kawasaki-shi, Kashihara-Shi, Shinjuku-ku, Suginami-ku
2021-02-23
Recruiting
PharmaEssentia Japan K.K.
Phase 3
67
Toon-shi, Tsu, Suita-shi, Bunkyo-ku, Shinjuku-ku, Chuo-shi
2021-01-19
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Recruiting
Eisai Co., Ltd.
Phase 1
18
Hakata, Kurume, Yuhu, Bukyo-ku, Mintato-ku, Shinjuku-ku, Kofu, Kyoto
2020-02-27
Active, closed
AstraZeneca
Phase 3
140
Chiba, Kita-gun, Sagamihara-shi, Sendai, Shinjuku-ku
2019-10-29
Recruiting
Eli Lilly and Company
Phase 3
190
Bunkyō, Chiba, Kagoshima, Kanazawa, Niigata, Saitama-shi, Sendai, Shinjuku-ku
2019-04-05
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Tōon, Sapporo, Shiwa-Gun, Sendai, Kawagoe, Kodaira, Shinjuku-ku, Chiba
2018-12-28
Active, closed
Eli Lilly and Company
Phase 3
533
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku, Tokyo
2018-03-14
Active, closed
NRG Oncology
Phase 3
162
Sapporo, Shiwa-gun, Mitaka-shi, Shinjuku-ku, Hiroshima, Saitama, Tokyo
2017-09-12
Active, closed
Bayer
Phase 3
24
Ōbu, Suita, Shinjuku-ku
2015-10-29
Active, closed
AstraZeneca
Phase 2
162
Chūōku, Fukuoka, Matsuyama, Morioka, Shinjuku-ku, Yamagata, Yonago-shi
2010-02-04
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Sendai, Kure, Sapporo, Shiwa-gun, Kagoshima, Niigata, Shizuoka, Shinjuku-ku
2007-12-06
Rows per page Showing 1–107 of 107
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/shinjuku-ku

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 107 of those studies with a site in Shinjuku-ku.

How many clinical trials are recruiting in Shinjuku-ku?

50 of the 107 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 51 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shinjuku-ku), 107 studies
PhaseStudiesRecruitingShare
Phase 3592255.1%
Phase 221919.6%
Not applicable635.6%
Phase 1/2655.6%
Phase 2/3655.6%
Phase 1544.7%
Phase 4312.8%
Observational110.9%

Most active sponsors

Lead sponsors with the most studies (Shinjuku-ku)
Lead sponsorStudiesRecruiting
AstraZeneca147
Novartis Pharmaceuticals143
Eli Lilly and Company136
AbbVie74
Pfizer65
Merck Sharp & Dohme LLC50
Takeda54
Alexion Pharmaceuticals, Inc.20
Alkermes, Inc.22
Amgen21
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.